ClinicalTrials.gg
CompletedNCT04331288Updated Dec 4, 2023

Effects of Ethanol on the Pharmacokinetics of PT-150 (Formerly ORG34517) (PT150 PK Study)

A Phase 1 interventional study of PT150 and Beverage in Potential Treatment for Alcohol Dependence-Alcohol Interaction, sponsored by Pop Test Oncology LLC. Completed at 1 site in United States. Open to participants aged 21 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-04.

Sponsored by Pop Test Oncology LLC · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2023, 3 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
21 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,073 studies in Alcoholism with a site in United States — 187 open to participants now, 227 under way, 15 of them phase 3. Alcoholism · United States.

Enrollment
896th of 989
10 · median 80
Started
2021
with 55 others
Phase 1
102 of 1,073
22 open now
Registered
727th of 1,073
by date

Among the 1,073 studies in Alcoholism with a site in United States, this one is the 896th largest by enrollment of the 989 interventional ones that give a count, is one of 56 that started in 2021, is one of 102 in phase 1, and was the 727th registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

187 of the 1,073 studies in Alcoholism with a site in United States are open now. Recruiting first, the newest first:

182 more — sign in →

All 187 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 21 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,073 studies in Alcoholism with a site in United States, or all of them as a file.
02

Study summary

The purpose of this clinical study is to assess pharmacokinetic interactions between ethanol (EtOH) and PT150 (900 mg qd) in non-treatment-seeking alcohol-experienced volunteers-(to include military service members, veterans and/or civilians).

Read the detailed description

This study can be classified as a phase 1, single center, and drug-drug interaction (DDI) study. The within-subjects' experimental procedures will assess pharmacokinetic interactions between ethanol (EtOH) and PT150 (900 mg qd) in non-treatment-seeking alcohol-experienced volunteers (to include military service members, veterans and/or civilians). The specific aim of this study is to evaluate the safety and tolerability of PT150 (a novel, selective Glucocorticoid receptor (GR) antagonist) in combination with alcohol and to determine the amount of PT150 and alcohol in blood (i.e., the pharmacokinetic (PK) interactions between alcohol and PT150) in 10 non-treatment seeking participants. The purpose of this study is to assess the possibility of any adverse interactions between alcohol and PT150. While PT150 might be effective in the treatment of AUD, because alcohol can affect the way that PT150 is metabolized in the body, we first need to determine 1) that it is safe to take PT150 in combination with alcohol, and 2) the amount of PT150 and alcohol in blood after PT150 has reached steady state. This study population will be drawn from adults of any race or ethnicity, males, and females who are post-menopausal, undergoing hormone replacement treatment at a stable dosage for at least 3 months, infertile and not hormone cycling, or using approved non-hormonal contraception for at least two weeks after the last dose. Potential enrollees will be drawn of those NOT seeking treatment for alcohol use disorder (AUD). Statistical goals for the study are to evaluate the pharmacokinetics of PT150 given in combination with exposure to alcohol. The primary objective includes assessing if measures of concentration and timing of PT150 levels in the blood differ between the PT150 challenge (challenge on Day 8 and continually observed through Day 9) in combination with alcohol (ethanol beverage) compared to the steady-state PT150 challenge, absent alcohol challenge, on Day 7. Secondary objectives are to determine if measures of concentration and timing of BAL in the blood differ between the active alcohol challenges only (Day 1/baseline) and PT150 challenges in combination with alcohol challenges (Day 8). Other secondary outcomes include evaluating health and safety outcomes as well as withdrawal from alcohol. After completion of the screening period, the remaining study duration will proceed as follows for each participant: Admission for an initial 1-day in-patient stay; Discharge followed by 4 days of outpatient visits; Readmission for a 4-day inpatient stay; and for females, a follow-up visit will be scheduled to occur at least 14 days after the final dose of PT150 is administered to ensure pregnancy has not occurred. This results in a total participant duration of 10 days.

03

Conditions studied

  • Potential Treatment for Alcohol Dependence-Alcohol Interaction

Keywords

  • Alcohol
  • Alcoholic
  • Alcoholism
  • Alcohol abuse
  • Alcohol interaction
  • Alcohol Use Disorder
  • Alcohol use
  • Alcohol dependence
  • Alcohol dependent
  • Post Traumatic Stress Disorder
  • Substance use Disorder
  • Ethanol abuse
  • Ethanol use
  • Pharmacokinetics
04

Who can participate

Ages eligible
21 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide signed and dated form;
  2. Male or female, aged 21-64;
  3. Must score \< 10 on the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar) assessed in the context of a BAL ≤ 0.00% to demonstrate that they do not need medical detoxification;
  4. Must have blood lab test results within the acceptable limits noted in the protocol (Tests may be repeated if initial results are out of range);
  5. Have normal vitals (heart rate 50-100 bpm, systolic blood pressure 90-140 mmHg and diastolic blood pressure 60-90 mmHg) and a baseline that demonstrates clinically normal sinus rhythm, clinically normal conduction, normal , and no arrhythmias;
  6. Have a self-reported medical history and brief physical examination demonstrating no clinically significant for study participation, in the judgment of the admitting physician;
  7. Must be willing to comply with all study procedures and be available for the duration of the study;
  8. Women must either be unable to conceive (i.e., surgically sterilized, sterile, or ) or using non-hormonal, medically acceptable during the study and for at least 2 weeks after the last dose of study drug has been given, with or without additional hormonal contraception. Women can be receiving hormone replacement treatment (HRT) as long as the HRT dose has been stable for a period of at least 3 months;
  9. Women must provide a negative urine pregnancy test within 30 days of alcohol administration on Day 1/baseline (i.e. during the screening period) and a negative serum pregnancy test on day 1 prior to alcohol administration and on day 5. Note that because participants are supervised 24-hours a day when they reside as inpatients, a urine pregnancy test is planned on day 9;
  10. Able to provide proof of age and identity (includes providing full name and date of birth).

Exclusion criteria

Exclusion Criteria:

  1. criteria for substance use disorders other than alcohol, nicotine, or marijuana or test positive for prescription or illegal substances other than THC. With regard to marijuana/THC, an individual must agree to abstain from marijuana/THC use three days prior to intake (Day 1/baseline);
  2. Be pregnant or nursing;
  3. Be receiving HRT where their dose has not been stable for a minimum of 3 months;
  4. To reduce variability in the magnitude of drug-drug interactions (DDIs), use of concomitant medications (except hormonal ) or OTC medications should be excluded for a sufficient time before subject enrollment (at least 14 days or 5 half-lives [whichever is longer]) and for the entire duration of the study. These items should be excluded for a longer time period if the DDI mechanism is induction or time-dependent inhibition. Concomitant medication use includes any prescription, over-the-counter medications or dietary/herbal/nutritional supplements;
  5. Be receiving any non-pharmacotherapy treatments or procedures for which there are precautions for taking concomitantly with PT150 and/or those that might interfere with the study;
  6. Have neurological or psychiatric disorders other than AUD or SUD for THC;
  7. History of suicide attempts and/or current suicidal ideation/plan;
  8. Have evidence of untreated or unstable medical illness including: cardiovascular, neuroendocrine, , renal, hepatic, or active +, AIDS infection;
  9. Have a history of medically adverse reactions to alcohol (e.g., loss of consciousness (LOC), chest pain, or epileptic seizure) or major alcohol-related medical complications requiring hospitalization (i.e. hepatitis or pancreatitis);
  10. Have (s) to take the study medications such as renal or hepatic impairment, congenital metabolic disorders, or to study medication class (i.e., antagonists);
  11. Have past brain injury/head trauma with current symptoms (e.g. not photophobic, dizziness, etc.) or past report of LOC for >30 minutes and/or have been blast-exposed or had LOC of >1 minute within the last 10 years and current post-concussive symptoms;
  12. Self-report more than thirty days' abstinence from alcohol during the three months prior to enrollment/consent;
  13. Current signs of violence or aggression assessed as part of the consent process;
  14. Participation in a pharmaceutical trial or exposure to drugs within 1 month of the screening visit;
  15. Be currently seeking treatment for AUD;
  16. Have any other illness, condition, or use medications (psychotropic or antiretroviral), which in the opinion of the PI and/or the admitting physician would preclude safe and/or successful completion of the study;
  17. A history of adrenal insufficiency or a baseline plasma cortisol level of ≤ 5mcg/dL;
  18. A baseline cortisol of > 5 mcg/dL BUT a post-ACTH stimulation cortisol of \<18 mcg/dL;
  19. Have been treated with any form of corticosteroid in the past 30 days;
  20. Have a history of endometrial hyperplasia, endometrial cancer, uterine polyps, or unexplained vaginal bleeding;
  21. Have potassium levels below the normal reference range;
  22. Men taking testosterone replacement therapy;
  23. Men or women currently interested in fertility;
  24. Have underlying inflammatory or auto-immune disorders;
  25. Have elevated thyroid stimulating hormone (TSH) levels;
  26. Have Type I diabetes.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    PT150 with alcohol consumption

    Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge will be completed on day 1 (pre-treatment) followed by blood draws over a 24-hour period. PT150 dosing will begin on study day 2 and continue until steady state is reached on day 6, at which point blood draws will occur over a 24-hour period. On day 7, after PT150 steady state has been achieved, an alcohol challenge will be completed followed by blood draws over a 40-hour period.

    Drug: PT150 · Other: Beverage

Interventions

  • DrugPT150

    Intervention 1 includes PT150 with alcohol consumption

    Also known as: Formerly ORG34517

  • OtherBeverage

    The alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in juice or another flavored beverage. Participants will be allowed 30 minutes to consume the beverages.

    Also known as: Ethanol beverage

06

What researchers measure

Primary outcomes

  1. Difference in maximum concentration of PT150 (CmaxPT150)

    Estimates of maximum concentration (Cmax) of PT150 will be calculated and compared from PT150 steady state alone (days 6-7) to concurrent steady state of PT150 with ethanol exposure (days 7-9).

    Time frame: from the PT150 blood draws (days 6-7) to the PT150 with concurrent ethanol blood draws (days 7-9)

  2. Difference in time of maximum concentration of PT150 (tmaxPT150)

    Estimates of time of maximum concentration (Tmax) of PT150 will be calculated and compared from PT150 steady state alone (days 6-7) to concurrent steady state of PT150 with ethanol exposure (days 7-9).

    Time frame: from the PT150 blood draws (days 6-7) to the PT150 with concurrent ethanol blood draws (days 7-9)

  3. Difference in terminal elimination half-life of PT150 (t1/2PT150)

    Estimates of terminal elimination half-life (T1/2) of PT150 will be calculated and compared from PT150 steady state alone (days 6-7) to concurrent steady state of PT150 with ethanol exposure (days 7-9).

    Time frame: from the PT150 blood draws (days 6-7) to the PT150 with concurrent ethanol blood draws (days 7-9)

  4. Difference in area under the concentration-time curve of PT150 (AUCPT150)

    Estimates of the area under the concentration curve (AUC) through 24 hours post-intervention of PT150 will be calculated and compared from PT150 steady state alone (days 6-7) to concurrent steady state of PT150 with ethanol exposure (days 7-9).

    Time frame: from the PT150 blood draws (days 6-7) to the PT150 with concurrent ethanol blood draws (days 7-9)

Secondary outcomes

  1. Difference in the maximum concentration of ethanol (CmaxEtOH)

    Estimates of maximum concentration (Cmax) of ethanol will be calculated and compared from ethanol alone (days 1-2) to concurrent steady state of PT150 with ethanol exposure (days 7-9).

    Time frame: from the ethanol alone blood draws (days 1-2) to the PT150 with concurrent ethanol blood draws (days 7-9)

  2. Difference in time of maximum concentration of ethanol (tmaxEtOH)

    Estimates of time of maximum concentration (Tmax) of ethanol will be calculated and compared from ethanol alone (days 1-2) to concurrent steady state of PT150 with ethanol exposure (days 7-9).

    Time frame: from the ethanol alone blood draws (days 1-2) to the PT150 with concurrent ethanol blood draws (days 7-9)

  3. Difference in terminal elimination half-life of ethanol (t1/2EtOH)

    Estimates of terminal elimination half-life (T1/2) of ethanol will be calculated and compared from ethanol alone (days 1-2) to concurrent steady state of PT150 with ethanol exposure (days 7-9).

    Time frame: from the ethanol alone blood draws (days 1-2) to the PT150 with concurrent ethanol blood draws (days 7-9)

  4. Difference in the area under the concentration-time curve of ethanol (AUCEtOH)

    Estimates of the area under the concentration curve (AUC) through 24 hours post-intervention of ethanol will be calculated and compared from ethanol alone (days 1-2) to concurrent steady state of PT150 with ethanol exposure (days 7-9).

    Time frame: from the ethanol alone blood draws (days 1-2) to the PT150 with concurrent ethanol blood draws (days 7-9)

  5. Difference in the number and severity of adverse events

    Difference in the overall number and proportion of adverse events compared among ethanol alone (days 1-2), PT150 alone (days 2-7), and PT150 with ethanol exposure (days 7-9). Comparisons will also be stratified by severity of adverse events.

    Time frame: Adverse events are reported throughout the study, from enrollment to study completion

  6. Difference in heart rate

    Difference in heart rate compared among ethanol alone (days 1-2), PT150 alone (days 6-7), and PT150 with ethanol exposure (days 7-9).

    Time frame: Heart rate is collected one time after the serial blood draws have been completed for each of ethanol alone (day 2), PT150 alone (day 7), and PT150 with ethanol exposure (day 9).

  7. Difference in systolic blood pressure

    Difference in systolic blood pressure compared among ethanol alone (days 1-2), PT150 alone (days 6-7), and PT150 with ethanol exposure (days 7-9).

    Time frame: Systolic blood pressure is collected one time after the serial blood draws have been completed for each of ethanol alone (day 2), PT150 alone (day 7), and PT150 with ethanol exposure (day 9).

  8. Difference in diastolic blood pressure

    Difference in diastolic blood pressure compared among ethanol alone (days 1-2), PT150 alone (days 6-7), and PT150 with ethanol exposure (days 7-9).

    Time frame: Diastolic blood pressure is collected one time after the serial blood draws have been completed for each of ethanol alone (day 2), PT150 alone (day 7), and PT150 with ethanol exposure (day 9).

  9. Change in severity of alcohol withdrawal symptom severity as measured on the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar)

    Change in CIWA-Ar total score from baseline (pre-PT150 exposure) to all post-PT150 exposure measurements.

    Time frame: The CIWA-Ar assessment is completed one time on day 1 prior to ethanol and PT150 exposure, followed by measurements on days 5, 6, 7, 8, and 9 (all post-PT150 exposure measurements).

  10. Change in ECG abnormalities

    Change in ECG abnormalities from baseline (pre-PT150 exposure) to all post-PT150 exposure measurements.

    Time frame: An ECG measurement is taken once on day 1 prior to ethanol and PT150 exposure, followed by measurements on days 2, 5, 6, 7, 8, and 9 (all post-PT150 exposure measurements).

07

Study locations

1 site
  • Michael E. DeBakey Veterans Affairs Medical Center
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: Yes — Data will be shared with a registry per the data sharing plans of the Consortium

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Oct 2023, 23 months.

Of 75 phase 1 interventional studies under Alcoholism, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2020
First posted
Apr 2, 2020
StartActual
Nov 1, 2021
Primary completionActual
Oct 27, 2023
CompletionActual
Oct 27, 2023
Last update
Dec 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04331288
Lead sponsor
Pop Test Oncology LLC
Collaborators
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, Congressionally Directed Medical Research Programs, Michael E. DeBakey VA Medical Center, Baylor College of Medicine
Responsible party
Sponsor
First posted
Apr 2, 2020
Start date
Nov 1, 2021
Primary completion
Oct 27, 2023
Completion
Oct 27, 2023
Last update
Dec 4, 2023

Study contacts

Christopher Verrico, PhD
principal investigator · Michael E. DeBakey Veterans Affairs Medical Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Org-34517

Start the discussion